Most research peptide suppliers compete on purity claims. A claim is not documentation. “≥98% pure” on a product page with no COA link, no lot number, no testing lab name, and no methodology cited is a marketing statement, not a quality standard. VialTrace was built to be the alternative.
What we test: HPLC purity by UV detection. LC-MS identity confirmation. Batch-specific results, not generic specifications. Why it is public: because buyers deserve to verify, not trust. Third-party lab: independent from our suppliers. No conflicts.
Qualified researchers. Academic laboratories. Biotech and pharmaceutical discovery teams. CROs and analytical labs. We do not sell to buyers who indicate intent to use products for human or veterinary administration. We refuse those sales and document the refusal.
GLP-1-related compounds (semaglutide, tirzepatide, retatrutide) are not in our Phase 1 catalog. They carry active FDA scrutiny, patent exposure from approved branded drugs, and compounding prohibition issues. We will not list compounds with unresolved IP or regulatory risk. Catalog expansion happens after counsel review, not before.